CRIMSON: A multicenter, randomized, sham-controlled, double-blind, 72-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal administration of BI 764524 in patients with moderate to severe non-proliferative diabetic retinopathy